Design
Review
Disulfidptosis targeting may offer novel CVD therapies; extends mechanistic insights but leaves open clinical validation.
Cardiovascular diseases (CVDs) remain the primary cause of death worldwide. Exploring novel therapeutic targets is important for defining future research directions in cardiovascular medicine. Considering the notable role of cell death in disease pathogenesis, targeting disulfidptosis may represent a valuable therapeutic strategy for CVDs. However, current research increasingly centers on cancer, and the role of disulfidptosis in the cardiovascular field remains insufficiently explored. Accordingly, the present review examines the mechanisms of disulfidptosis across different cardiac cell types: Cardiomyocytes, vascular smooth muscle cells, endothelial cells and fibroblasts. Furthermore, the review discusses existing evidence for disulfidptosis in CVDs and potential intervention strategies, aiming to provide new perspectives for preventing and treating CVDs.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: